The four PAR family members are G protein coupled receptors that are normally activated by proteolytic exposure of an occult tethered ligand. Three of the family members are thrombin receptors. The fourth (PAR2) is not activated by thrombin, but can be activated by other proteases, including trypsin, tryptase and Factor Xa. This review focuses on recent information about the manner in which signaling through these receptors is initiated and terminated, including evidence for inter-as well as intramolecular modes of activation, and continuing eorts to identify additional, biologicallyrelevant proteases that can activate PAR family members. Oncogene (2001) 20, 1570 ± 1581.
Introduction
Ten years after the identi®cation of the ®rst proteaseactivated G protein coupled receptor, now known as PAR1, the basic principles of its mechanism of activation have become familiar. Unlike most G protein coupled receptors, PAR1 has an intrinsic ligand within its extended N-terminus that is exposed proteolytically by thrombin, creating a neo-N-terminus that serves as a tethered ligand for the receptor ( Figure  1 ). The extracellular domains of the receptor form the ligand binding site, presumably triggering a conformational change in the receptor that in turn leads to guanine nucleotide exchange on associated G proteins and initiates intracellular signaling. Since this basic mechanism has been well covered elsewhere (Grand et al., 1996; DeÂ ry et al., 1998; Coughlin, 2000) , this review will primarily focus on recent discoveries concerning receptor activation and inactivation, the evidence for intermolecular relationships among PAR family members, and eorts to identify additional, biologicallyrelevant proteases that can activate PAR family members.
The current PAR family members
Four PAR family members have been identi®ed to date. Three (PAR1, PAR3 and PAR4) are thrombin receptors. The fourth, PAR2, is activated by serine proteases other than thrombin (Table 1) . PAR1 was initially identi®ed using RNA derived from thrombinresponsive cells and of the four current family members it is still the one about which there is the most known (Rasmussen et al., 1991; Vu et al., 1991a) . It is also the one that established the activation paradigm that in general terms applies to the other three family members (Vu et al., 1991a) . That paradigm includes the ability of these receptors to respond not only to selected proteases, but also to peptides based upon the sequence of the tethered ligand. The one exception to the rule is PAR3 for which no activating peptide agonist has been discovered. In contrast to PAR1, PAR2 was cloned serendipitously and only subsequently found to be activated by trypsin (Nystedt et al., 1994 (Nystedt et al., , 1995a . PAR3 was identi®ed as a second thrombin receptor when gene ablation studies showed that platelets from mice lacking PAR1 were still responsive to thrombin (Connolly et al., 1996) . It is a major regulator of thrombin responses in rodent platelets (Ishihara et al., 1997) , but little else is known about it. When overexpressed, human PAR3 can respond to thrombin by a mechanism that was initially thought to resemble PAR1. However, recent evidence suggests that on murine platelets PAR3 serves solely to facilitate the cleavage of PAR4 at low thrombin concentrations and does not directly activate G proteins (NakanishiMatsui et al., 2000) . The fourth family member, PAR4, was identi®ed by database searches using conserved domains of the other three family members (Kahn et al., 1998b; Xu et al., 1998) . PAR4 is expressed on human and mouse platelets and presumably accounts for the continued ability of platelets from PAR3 knockout mice to respond to thrombin (Kahn et al., 1998b; Xu et al., 1998) .
Thus, the four PAR family members share a number of similarities, but some dierences have emerged. As noted above, three of the receptors can be activated by thrombin. Two of these, PAR1 and PAR3, have similar dose/response curves when studied in expression systems. The third, PAR4, requires 10 ± 100-fold higher concentrations of thrombin, apparently because it lacks the hirudin-like sequences that can interact with thrombin's anion-binding exosite and facilitate receptor cleavage (Kahn et al., 1998b; Xu et al., 1998; Nakanishi-Matsui et al., 2000) .
PAR genetics and tissue distribution
The genes encoding all four family members have a similar structure with a single intron interrupting the sequence encoding the receptor N-terminus. Similarities between PARs extend to their genetic loci, which are conserved across species, and suggest a common ancestral origin (Kahn et al., 1998a) . In humans PAR1, PAR2, and PAR3 are tightly clustered at chromosome 5q13, while PAR4 is located separately at 19p12 (Xu et al., 1998; Kahn et al., 1998a) . In mice PAR1, PAR2 and PAR3 are in a cluster that maps to 13d2 and PAR4 is located at 8b3 (Kahn et al., 1998a) . If genes for additional PAR family members exist, they have not yet been identi®ed.
Information about the tissue distribution of the four PAR family members has been obtained by a number of approaches and is most complete for PAR1 and PAR2, since antibodies for these receptors are widely available. These receptors are found in a variety of tissues and cell lines, and have been described in several species and during embryonic development (recently reviewed in DeÂ ry et al. (1998) , see also Jenkins et al. (2000) ). The patterns of expression of PAR3 and PAR4 are less well characterized, and rely primarily upon analyses of mRNA expression. Interestingly, while human PAR3 is widely and abundantly expressed, mouse PAR3 is highly expressed only in megakaryocytes, bone marrow, and spleen (Ishihara et al., 1997) . Human PAR4 mRNA is abundant in gastrointestinal tissues including the liver, small Figure 1 Structure and features of PAR1. Cartoon of human PAR1 highlighting domains thought to be involved in receptor activation and interactions with thrombin. Additional details and references are included in the text. Potential sites for N-linked glycosylation are marked with an asterisk. L258P, D199R.R199D and Y371A/Y372A/Y373A are some of the known induced mutations that will inactivate PAR1. There are no known naturally occurring PAR1 mutants that result in receptor inactivation Oncogene Protease-activated receptors PJ O'Brien et al intestine, and pancreas, as well as in megakaryocytes, lung, placenta, thyroid, and prostate tissues (Xu et al., 1998; Kahn et al., 1998b) . Whether the receptor is actually expressed in all of those tissues remains to be demonstrated.
It is not unusual for more than one PAR family member to be present in the same cell. Examples include human platelets, which express PAR1 and PAR4 (Kahn et al., 1999; Xu et al., 1998) , mouse platelets, which express PAR3 and PAR4 (Kahn et al., 1998b) , and human endothelial cells, which express PAR1, PAR2 and possibly PAR3 (Schmidt et al., 1998; O'Brien et al., 2000) . In both humans and mice, PAR1 appears to be the most widely-expressed of the three thrombin-responsive PAR family members. Despite this, the`knockout' of PAR1 in mice was not uniformly lethal (Connolly et al., 1996; Darrow et al., 1996; Damiano et al., 1999) . Instead, half the mice developed normally in the absence of PAR1, while the other half died at embryonic day 9, apparently from the absence of the normal contribution of PAR1 to the development of a stable vasculature. Absence of PAR1 from other sites in which it is normally expressed had no obvious eect. PAR1 knockout mice show altered responses to vascular injury, suggesting that this receptor plays a role in extracellular matrix regulation in the vasculature . PAR2 and PAR3 knockout mice appear to develop normally Kahn et al., 1998b) , suggesting functional redundancies or crosstalk among the family members.
Which receptor(s) contribute to thrombin responses in any particular cell?
In light of the knockout studies, and considering species-and tissue-speci®c dierences in PAR expres- (Jia et al., 1999) concentrations; no mice (Connolly et al., 1996;  embryonic loss Darrow et al., 1996) ( Activating proteases for PAR1: Thrombin (Vu et al., 1991a; Rasmussen et al., 1991) . Trypsin (Vouret-Craviari et al., 1995b; Xu et al., 1998; Vu et al., 1991a) . Factor Xa (Molino et al., 1997c; Riewald et al., 2000) . Granzyme A (Suidan et al., 1994 (Suidan et al., , 1996 .
c Structure/activity relationships have been explored in some detail for short peptides (up to 14 amino acids) that activate PAR1 and PAR2 Scarborough et al., 1992; Al-Ani et al., 1999; Hollenberg et al., 1992 Hollenberg et al., , 1997 Blackhart et al., 1996; Chao et al., 1992; Natarajan et al., 1995; Kawabata et al., 1999) , and more recently for PAR4 (Kahn et al., 1998b (Kahn et al., , 1999 Hollenberg et al., 1999; Faruqi et al., 2000) . To date, no peptide activators of PAR3 have been described (Hollenberg, 1999) . d Optimal activation of PAR2 by factor VIIa appears to require co-expression of tissue factor (TF) and the presence of factor X (Camerer et al., 2000) . Under these conditions the concentration of factor VIIa that is required to elicit signaling thru PAR2 drops to 8 pM (EC 50 ). This basic phenomenon was obnserved in several mammalian cell lines, umbilical vein endothelial cells and injected Xenopus laevis ocytes (see references below, although not in baby hamster kidney (BHK) cells (Peterson et al., 2000) . It does not require the cytoplasmic domain of tissue factor (Sorensen et al., 1999; Camerer et al., 2000) . Tryptase is able to cleave and activate PAR2, but with a potency that is much less than trypsin. Trypsin (Nystedt et al., 1994; Alm et al., 2000) . Tryptase (Molino et al., 1997b; Corvera et al., 1997; Schechter et al., 1998; Alm et al., 2000) . Factor Xa (Parry et al., 1996; Camerer et al., 2000) . TF/VIIa (Camerer et al., 1999 (Camerer et al., , 2000 . MT-SP1 (Takeuchi et al., 2000) .
e Inactivating proteases for PAR1: Plasmin (Vouret-Craviari et al., 1995b; Parry et al., 1996) . Cathepsin G (Molino et al., 1995; Renesto et al., 1997) . Elastase (Renesto et al., 1997) . Proteinase 3 (Renesto et al., 1997) . f Activating proteases for PAR3: Thrombin (Connolly et al., 1996; Ishihara et al., 1997) . Activating proteases for PAR4: Thrombin (Kahn et al., 1998b) . Trypsin (Kahn et al., 1998b) . Cathepsin G (Sambrano et al., 2000) . g PAR1 antagonists: (Bernatowicz et al., 1996; Hoekstra et al., 1998; McComsey et al., 1999; Andrade-Gordon et al., 1999; Kawabata et al., 1999) sion, a meticulous, tissue by tissue approach may be required to better understand the role of PARs in development and homeostasis. Determining which receptor mediates protease responses in a particular cell or tissue is not necessarily straight-forward. Cells can express more than one PAR family member and more than one may be thrombin-responsive. Variations in expression level, dierential sensitivity to proteases, species dierences, and a shortage of selective agonists and antagonists complicate the task further. Some of this will undoubtedly sort itself out with time as better agonists and antagonists become available. Several small molecule PAR1 antagonists have already been described (Hoekstra et al., 1998; Bernatowicz et al., 1996; Hung et al., 1992b; Seiler et al., 1995; McComsey et al., 1999; Doorbar and Winter, 1994; AndradeGordon et al., 1999) . Many of them are derived from the sequence of the peptide ligand for PAR1 and, due to structural similarities in activating peptides discussed below, can potentially inhibit PAR2 as well. These antagonists work by blocking the interaction of the newly exposed tethered ligand with its binding sites within the extracellular domains of receptor. They do not inhibit thrombin, nor do they prevent receptor cleavage. Currently, no PAR2, PAR3 or PAR4 antagonists are available.
In the absence of antagonists to other PARs, researchers have relied heavily upon agonist peptides to examine PAR signaling in primary tissues and cell lines. Early studies of PAR1 used agonist peptides that were later shown to activate PAR2 (Blackhart et al., 1996; Hollenberg et al., 1997) . Over time, relatively speci®c agonist peptides have been described for PAR1, PAR2, and PAR4 (Table 1) (Blackhart et al., 1996; Xu et al., 1998; Faruqi et al., 2000; Hollenberg et al., 1997; Brass et al., 1992) . In some cells, one can now tease out contributions from individual PAR subtypes, and con®rm distribution data with functional correlates of receptor expression. For example, several recent reports have used agonist peptides to con®rm PAR4 expression in platelets (Xu et al., 1998; Kahn et al., 1998b; Shapiro et al., 2000; Faruqi et al., 2000) as well as in gastric and vascular smooth muscle cells . Still, responses to these agonists (even in combination) may not accurately recreate responses to proteases, and in cells that express PAR3 along with PAR1 or PAR4 it is still necessary to use thrombin. In such cells it has been necessary to combine several approaches to dissect the thrombin signal.
As an illustration of one approach to dissecting thrombin responses, we have recently used a combination of a PAR1 antagonist (BMS200261) (Bernatowicz et al., 1996) and a pair of monoclonal antibodies that can block cleavage of PAR1 to study the basis of thrombin responses in human umbilical vein endothelial cells (HUVEC) (O'Brien et al., 2000) . HUVEC express abundant amounts of PAR1 and PAR2 on their surface (Nelken et al., 1992; Molino et al., 1997c; D'Andrea et al., 1998; Bahou et al., 1993; Mirza et al., 1996; Nystedt et al., 1996; Ngaiza et al., 1992; Woolkalis et al., 1995a,b) and at least one report suggests that PAR3 is present as well, albeit at lower densities (Schmidt et al., 1998) . Responses to thrombin in endothelial cells include an increase in the cytosolic Ca 2+ concentration. To determine whether all of this increase is mediated by PAR1, we measured changes in cytosolic Ca 2+ in the presence of two monoclonal antibodies, ATAP2 and WEDE15, that respectively target the PAR1 tethered ligand domain and the hirudin-like sequence that promotes thrombin binding and receptor cleavage (Brass et al., 1994; Hoxie et al., 1993) . When added together, they completely prevented cleavage of PAR1 by thrombin, and completely blocked the increase in Ca 2+ otherwise seen with thrombin. Therefore, at least for these cells, cleavage of PAR1 appears to be essential for the thrombin response. By comparison, the PAR1 antagonist, BMS200261, was only partially eective in preventing HUVEC responses to thrombin despite the fact that in separate experiments with cell lines, BMS200261 was found to completely block thrombin signaling through PAR1 and not to cross-antagonize PAR2. The remaining thrombin response on HUVEC in the presence of BMS200261 proved to be due to transactivation of PAR2 by cleaved PAR1, a mechanism that is discussed later in this review. A similar approach has been used to dissect the contributions of PAR1 and PAR4 to thrombin responses in human platelets, taking advantage of antibodies that block each of these receptors (Kahn et al., 1999) . In contrast to the results obtained with HUVEC, those studies show that both PAR1 and PAR4 contribute to platelet thrombin responses, especially at the higher concentrations of thrombin necessary to activate PAR4.
The contribution of PAR3 to signaling in primary cells has been examined primarily in mouse platelets (Ishihara et al., 1997; Nakanishi-Matsui et al., 2000) and to a lesser extent human endothelial cells. In neither case was it possible to demonstrate a signal originating directly from PAR3, despite the fact that human PAR3 is expressed in ®broblasts clearly mediates responses to thrombin. That includes activating phospholipase C with an eciency comparable to that of transfected PAR1 and PAR2 (Ishihara et al., 1997 and our unpublished results). Barring new evidence for expression elsewhere, the current model is one in which mouse PAR3 is expressed exclusively on platelets where it has evolved to function as a coreceptor to facilitate PAR4 cleavage by thrombin but has lost the ability to signal independently. The biological role of human PAR3, however, remains elusive.
Ligand binding domains
Characterization of the ligand binding domain for PAR tethered ligand domains is most complete for PAR1 and PAR2. These receptors are approximately 30% identical to each other with near-identity of sequence within the second extracellular loop (ECL2), a region implicated in ligand docking (Nystedt et al.,
Oncogene Protease-activated receptors PJ O'Brien et al 1995a; Lerner et al., 1996; Al-Ani et al., 1999) . The ®rst studies of the PAR1 ligand binding domain used antibodies to inhibit activation of the receptor by thrombin and the peptide agonists, SFLLRN. Two dierent polyclonal antibodies were used, one raised against the entire receptor N-terminus, the other raised against a 20 residue peptide spanning the thrombin cleavage site (Bahou et al., 1993 (Bahou et al., , 1994 . The latter antibody prevented PAR1 activation by thrombin, but not by SFLLRN. The former blocked PAR1 activation by both, suggesting that it might target the ligand binding site. Follow-up studies showed that the antiserum raised against the entire N-terminus contains antibodies to the membrane-proximal region (residues 83 ± 94), implicating this domain in ligand binding (Bahou et al., 1994) (Figure 1) .
In subsequent studies, the ligand binding domain was mapped using chimeras between human and Xenopus PAR1 (Nanevicz et al., 1995; Gerszten et al., 1994) . Those studies also highlighted a region of the Nterminus near the ®rst transmembrane domain, as well as the second extracellular loop. Selected point mutations suggested that a residue in the membraneproximal amino terminal exodomain (Phe 87) and a residue in ECL2 (Glu 260) are sucient to confer selectivity for the PAR1 agonist peptides. The interaction of ECL2 with the SFLLRN ligand peptide was determined to occur between Glu 260 and Arg 46 in the tethered ligand domain, and to a lesser extent Phe 87 in the membrane-proximal amino terminal exodomain. Nanievicz and co-workers (1996) also found that insertion of eight residues of Xenopus ECL2 into human PAR1 produces a constitutively active receptor.
In a similar approach, Lerner et al. (1996) took advantage of the fact that while SFLLRN will activate both PAR1 and PAR2, SLIGRL will activate only PAR2 (Blackhart et al. 1996) and created chimeric gain-of-function receptors to determine which receptor domains specify agonist selectivity. Again, the results suggest that ECL2 confers most of the agonist selectivity. An additional interaction between the amino-terminal exodomain and the third extracellular loop (ECL3) was also demonstrated. Substituting either domain caused a loss of responsiveness to any agonist, but the double substitution created a functional receptor. Taken together, the chimera studies suggest that the extracellular domains of proteaseactivated receptors interact to form a ligand binding site that is critical for signaling.
Residues for ligand-induced PAR2 activation have also been identi®ed in ECL2. All of the PAR family members cloned to date have a common CHD motif in ECL2 (Xu et al., 1998) , which is found in PAR1 and PAR2 as part of the shared sequence, LNITTCHDVL. This domain is immediately followed by the residues N 259 ETL 261 in human PAR1, and P 231 EQL 234 in human PAR2 (Nystedt et al., 1995a) . Given the similarities between PAR1 and PAR2 activating peptides, and the ability of the former to activate PAR2 as well as PAR1, the ECL2 domains distal to the region of homology were analysed for their ability to confer agonist selectivity. A recent report described a complementation strategy similar to that used by Nanievicz et al. (1995) and Lerner et al. (1996) to study PAR1. In this case, Al-Ani et al. (1999) showed that the acidic region distal to the highly homologous CHDVL domain plays an important role in governing agonist activity. Complementation studies further showed that SFLLRN and SLIGRL interact in distinct manners with PAR2, and that SFLLRN interacts with PAR1 dierently than it does with PAR2.
Protease interactions: enabling and disabling
Although PAR1 was ®rst identi®ed as a thrombin receptor and PAR2 was originally reported as a trypsin receptor, it is now clear that interactions with other proteases are possible for both receptors and that any protease that uniquely cleaves the correct peptide bond within the N-terminus may be able to expose the tethered ligand and activate the receptor. Conversely, proteases that cleave elsewhere in the N-terminus may prevent receptor activation by amputating the tethered ligand domain. Depending upon where the additional cleavage occurs, it may also prevent receptor activation by peptide agonists. The widest experience to data with alternative' proteases has been with PAR1 (Table 1) . In addition to thrombin, human PAR1 can be activated by factor Xa (Molino et al., 1997c) , granzyme A (Suidan et al., 1994 (Suidan et al., , 1996 and trypsin (VouretCraviari et al., 1995b; Xu et al., 1998; Vu et al., 1991a) . PAR1 can be disabled by cathepsin G (Molino et al., 1995; Renesto et al., 1997) , plasmin (Vouret-Craviari et al., 1995b; Parry et al., 1996) , elastase (Renesto et al., 1997) and proteinase 3 (Renesto et al., 1997) . The fact that so many dierent proteases can cleave the Nterminus of PAR1 suggests that this part of the receptor is readily available on the surface of cells that express it. This conclusion is supported by the observation that, with minimal re-engineering of the residues N-terminal to the cleavage site, the protease preference of the receptor can be changed from thrombin to enterokinase (Vu et al., 1991b; Hung et al., 1992c) .
PAR1
The search continues for additional biologicallyrelevant proteolytic activators of the four PAR family members. A number of additional candidates have been identi®ed and several basic themes have emerged. Thrombin is the most potent activator of PAR1 and PAR3, cleaving them with the highest eciency of any protease. This eciency is likely derived from the structural interactions between thrombin's anion binding site and the receptor N-terminus, an interaction not yet seen between PAR2 or PAR4 and any of their activating proteases. The ability of other serine proteases in the coagulation cascade to activate PAR1 has been the subject of several studies. Factor Xa and, more recently, the tissue factor (TF)/factor VIIa complex have received the most attention because of their structural similarities to thrombin and their localization the surface of activated platelets and endothelial cells. The results have not been entirely consistent. Factor Xa will stimulate Ca 2+ release from Xenopus laevis oocytes expressing human PAR1, as will factor VIIa provided tissue factor is co-expressed with the receptor (Camerer et al., 2000) . Riewald et al. (2000) have also found that factor Xa will activate PAR1. In retrospect, the failure to detect a VIIa response in earlier studies could be due to the absence of tissue factor expression on HUVEC under normal conditions. Additional proteases that can activate PAR1 are listed in Table 1 .
In addition to activating PAR1, several proteases have now been shown to inactivate the receptor. One of the ®rst was cathepsin G. Cathepsin G is released from neutrophils at sites of in¯ammation reaching estimated concentrations as high as 0.5 mM (Weksler et al., 1989) . We found that cathepsin G cleaves human PAR1 between Phe 55 and Trp 56, removing the tethered ligand domain and preventing subsequent activation by thrombin, but apparently leaving the receptor otherwise intact since it still responds to SFLLRN (Molino et al. 1995) . This was con®rmed by Renesto et al. (1997) who also showed that two other neutrophil proteases, elastase and proteinase 3, had much the same eects and were capable of cleaving peptides corresponding to the PAR1 N-terminus near the tethered ligand domain. Recent ®ndings indicate that exposure to cathepsin G and elastase also disables signaling through human PAR3, while cathepsin G, but not elastase, prevents murine PAR3 from facilitating PAR4 cleavage at low thrombin concentrations. Interestingly, the inactivation of human PAR3 by cathepsin G and elastase appears to involve a mechanism other than amputation of the tethered ligand domain (M Molino et al., unpublished observations).
Cathepsin G has dierent eects on dierent cells, acting as an agonist in some cases and as a disabling protease in other (Selak et al., 1988; Molino et al., 1992; LaRosa et al., 1994; LeRoy et al., 1984; Totani et al., 1994) . For example, cathepsin G causes an increase in cytosolic Ca 2+ in human platelets, but has no apparent agonist eect on human endothelial cells or ®broblasts, despite the fact that PAR1 is present on all three. A recent report provides an explanation for these observations by showing that cathepsin G is an agonist for PAR4 (Sambrano et al., 2000) . Human platelets express PAR4, endothelial cells and ®broblasts do not. Cathepsin G prevents thrombin responses in cells that express only PAR1, while activating cells that express PAR4 (or PAR4 in combination with PAR1). The physiologic signi®cance of these disparate eects remains to be established. Finally, plasmin, which is best known for its ability to cleave ®brin, is also capable of cleaving and disabling PAR1 (Parry et al., 1996) .
PAR2
The high degree of homology of PAR2 and PAR1 led Nystedt et al. (1994) to analyse a number of serine proteases to determine that trypsin activates PAR2. Although PAR2 in the digestive tract might reasonably be expected to come into contact with trypsin, it is not at all clear that trypsin would ever gain access to PAR2 at the other sites in which the receptor is normally expressed. As a result, eorts have been made to identify additional activating proteases for PAR2. Two have been reported: tryptase and, more recently, the tissue factor/VIIa/Xa complex. Tryptase is a serine protease that is expressed at high concentrations in mast cells, and released by the mast cell at sites where they are activated (Caughey, 1994) . There are at multiple forms of the enzyme. Tryptase puri®ed from human skin can activate PAR2, and cells expressing PAR2 (including endothelial cells) can respond to tryptase in a manner similar to that seen with PAR2 activating peptides (Molino et al., 1997b) .
The original searches for proteases capable of activating PAR2 included serine proteases in the coagulation cascade. Factor Xa was found to cleave peptides corresponding to the PAR2 N-terminus at the site that would expose the tethered ligand domain, but the kinetics were much slower than with trypsin (Parry et al., 1996; Riewald et al., 2000) . Factor VIIa appeared to have no eect. However, two recent studies by Camerer et al. (1999 Camerer et al. ( , 2000 show that PAR2 can be activated by factor VIIa, but this occurs optimally only when the VIIa is bound to tissue factor (TF) on the cell surface and factor X is present. Under these conditions, factor VIIa (and Xa) activate PAR2 with an EC 50 of approximately 8 pM. On HUVEC these conditions are met only when tissue factor expression has been up-regulated by exposing the cells to TNF-a, which may explain the negative results that were obtained in some studies. The actual cleavage of PAR2 in the studies by Camerer et al. (2000) appeared to be mediated by either VIIa itself or by Xa, and did not appear to involve generation of thrombin ± which would not be expected to activate PAR2 ± but could activate the PAR1 that is also abundantly expressed by endothelial cells. These results suggest that VIIa and Xa may activate PAR2 best when they have been localized to the cell surface ± VIIa by an interaction with tissue factor, and Xa by binding to cell surface phospholipids. This may account for the negative results that were obtained in two studies in which tissue factor and PAR2 were co-expressed in CHO cells (Camerer et al., 1999) or in BHK cells (Petersen et al., 2000) .
Nonlinear mechanisms of activation that require interactions between receptors
Although intramolecular activation by a newly-exposed tethered ligand domain appears to be the standard for PAR family members, intermolecular activation has Oncogene Protease-activated receptors PJ O'Brien et al now been demonstrated in three cases: the activation of intact PAR1 by cleaved PAR1 , the activation of PAR2 by cleaved PAR1 (O'Brien et al., 2000) and, as already described, the activation of PAR4 by thrombin bound to PAR3. The ®rst two instances involve the presentation of the cleaved PAR1 N-terminus as a ligand to another receptor molecule, which is then activated without being cleaved. This is clearly not the preferred mechanism of activation in either of these cases. However, it provides an alternative that may become increasingly relevant when receptor antagonists are present. The fact that it can occur at all speaks to the close physical proximity of these receptors.
Transactivation of PAR1 by PAR1
Intermolecular liganding or transactivation was ®rst demonstrated in Xenopus oocytes expressing a PAR1 variant lacking its N-terminus (D-AMINO) and a chimera comprised of the PAR1 N-terminus fused to the transmembrane domain of CD8 (ATE-CD8) . When either PAR1 D-AMINO or ATE-CD8 was expressed alone, no thrombin responses were seen. When both were expressed together, thrombin signaling was rescued. This form of transactivation was approximately 1000 times less ecient than intramolecular signaling by wild type PAR1. Transactivation could also be demonstrated with full-length PAR1 mutants that were cleavable, but incapable of signaling, either because of a substitution of DR for RD in thè DRY box' for G protein coupling (Franke et al., 1990) or mutated the YYY motif (Y371A, Y372A, Y373A) in the distal seventh transmembrane domain. These receptor variants supported thrombin signaling only when co-expressed with D-AMINO PAR1. They did not complement each other, suggesting that receptor dimerization, which has been shown to occur for other G protein coupled receptors (Salahpour et al., 2000) , does not occur for PAR1.
Transactivation of PAR2 by cleaved PAR1
The ability of peptides corresponding to the PAR1 tethered ligand domain sequence (SFLLRN) to activate PAR2 (Blackhart et al., 1996; Hollenberg et al., 1997) raises the possibility that cleaved PAR1 could activate PAR2. On cells such as endothelial cells where both receptors are expressed, this could theoretically allow PAR2 to contribute to the thrombin response without being directly cleaved and activated by thrombin. To see whether this could occur, we recently examined thrombin responses in COS-7 cells coexpressing PAR2 with a PAR1 variant, PAR1 (L258P), that can be cleaved, but not activated by thrombin because of the mutation in ECL2 (Figure 1 ) (O'Brien et al., 2000) . Phosphoinositide hydrolysis was used as an index of receptor activation. There was no response to thrombin when either PAR1 (L258P) or PAR2 was expressed alone, but when the receptors were co-expressed, the response was surprisingly robust ± averaging about 40% of the signal observed with wild type PAR1 alone .
To determine whether transactivation could occur on endothelial cells with naturally-occurring forms of the two receptors, umbilical vein endothelial cells (HU-VEC) were preincubated with the PAR1 antagonist, BMS200261, at a concentration that completely blocked thrombin signaling on cells expressing only PAR1. Even at high concentrations BMS200261 blocked at most 75% of the response to thrombin. The remaining 25% of the thrombin response was blocked by desensitizing PAR2 (O'Brien et al., 2000) . These results suggest that PAR2 can be activated by cleaved PAR1 on endothelial cells and allow PAR2 to contribute to the thrombin response ± at least when a selective PAR1 antagonist is present. The fact that even in the absence of the antagonist, selective activation and desensitization of PAR2 reduces subsequent responses to thrombin (Mirza et al., 1996; Molino et al., 1997c; O'Brien et al., 2000) suggests that transactivation of PAR2 by cleaved PAR1 may also occur normally.
Transactivation of PAR2 by PAR1 has several implications. First, it suggests that PAR1 and PAR2 are located suciently closely to each other in the endothelial cell plasma membrane that the cleaved Nterminus of PAR1 can access PAR2. PAR1 and PAR2, like other receptors, are likely to be clustered in caveolae or other membrane microdomains (reviewed in Okamoto et al., 1998) . If so, the density of the receptors within these domains may allow transactivation to occur. Transactivation also has implications for the development of PAR1 antagonists. As was already noted, one approach to antagonist development has been to ®nd molecules that selectively inhibit PAR1 activation by peptide agonists. On platelets, the ecacy of this type of inhibitor is limited by the presence of PAR4. The present studies predict that on cells such as endothelial cells where both PAR1 and PAR2 are present, the ecacy of PAR1 tethered ligand antagonists will be limited by the presence of PAR2 even if other thrombin receptors are not present. If the contribution of transactivation is great enough, then other strategies will be required to prevent thrombin responses in target cells that express PAR2 along with PAR1.
Production of graded responses
The enzymatic nature of the activating protease and the novel tethered ligand activation mechanism pose a unique set of problems with regard to the duration of PAR signals in response to proteolysis. First, how does a catalytic protease such as thrombin elicit a concentration-dependent response in cells? Second, how does a tethered ligand, which is not removed from the cell surface after receptor activation, stop signaling? It is known that thrombin exerts its eects on target cells in a concentration-dependent manner (Shuman, 1986; Paris and PouysseÂ gur, 1986; Detwiler and Feinman, 1973a,b; Martin et al. 1975 Martin et al. , 1976 RittenhouseSimmons, 1979) . Receptors for neurotransmitters and soluble peptide ligands typically elicit such graded cellular responses through varied receptor occupancy. Since even low concentrations of thrombin would be expected to eventually cleave all the available receptors on the cell surface, how might a cell detect dierences in protease concentrations? The cloning of PAR1 enabled the analysis of this phenomenon.
Graded responses to PAR1 activation were demonstrated ®rst in transfected ®broblasts using either wild type receptor or a PAR1 variant that could be activated by enterokinase (Hung et al., 1992a,c; Vu et al., 1991b) . Ishii et al. (1993) examined the kinetics of receptor cleavage and found that it was proportional to the thrombin concentration. After cleavage, approximately 20 ± 60% of cleaved receptors remained on the cell surface, suggesting that receptor internalization was incomplete. Despite the continued presence of cleaved receptors and their exposed tethered ligands on the cell surface, signaling appeared to stop. When receptor cleavage was correlated with phosphoinositide hydrolysis, IP 3 formation was proportional to the absolute amount of cleaved receptor, but the subsequent increase in cytosolic Ca 2+ occurred only if 1,4,5-IP 3 was generated quickly enough to accumulate. In other words, the graded quality and the magnitude of the thrombin response mediated by PAR1 are determined by both the rate and extent of receptor cleavage. At high thrombin concentrations, receptors are cleaved more rapidly than at low concentrations, hence a greater response is seen. A less ecient rate of PAR1 cleavage may account for the inability of proteases other than thrombin to consistently produce equipotent PAR1-mediated signals.
Mechanisms of receptor inactivation and replacement
Once activated by a protease, PAR family members need to be turned o to prevent inde®nite signaling. They also need to be replaced in order to permit a second round of responses to the protease. How this is accomplished varies among the family members and in dierent cells. Several mechanisms for terminating signaling through other G protein coupled receptors also apply to PAR family members. These include receptor desensitization, which uncouples receptors from their G proteins, receptor endocytosis, which removes cleaved receptors from the cell surface, and receptor down-regulation, which leads to a reduction in total receptor number (see Figure 2 and BoÈ hm et al., 1996) . In some case, proteolysis of the tethered ligand domain may also play a role .
Indirect evidence for the role of receptor phosphorylation in PAR1 signal termination was ®rst obtained in studies of megakaryoblastic cells when it was shown that the recovery of signaling through receptors that had been activated by peptide agonists could be retarded by adding inhibitors of serine/threonine phosphatases . Proof that phosphorylation of PAR1 actually occurs was obtained by Van Obberghen-Schilling and co-workers using an epitopetagged PAR1 construct expressed in CCL39 cells (Vouret-Craviari et al., 1995a,b) . Ishii et al. (1994) later showed that co-expression of PAR1 with the kinase, GRK-3 (bARK-2), in Xenopus laevis oocytes selectively inhibits PAR1 signaling. This selectivity was later demonstrated in vivo, when transgenic mice overexposing GRK-3 were shown to have signi®cantly attenuated thrombin signaling (Iaccarino et al., 1998) . Over-expression of GRK-5 in endothelial cells caused a decrease in thrombin responses (presumably mediated by PAR1), while a kinase-dead form of GRK-5 (K215R) appeared to prolong thrombin responses (Tiruppathi et al., 2000) . Serine and threonine residues in the C-terminal cytoplasmic domain of PAR1 represent potential sites of phosphorylation by GRK family members and protein kinase C. Truncation of the C-terminus of PAR1 at residue 397 or replacement of all of the serine and threonine residues with alanine renders PAR1 insensitive to GRK-3 regulation (see Figure 1 and Ishii et al., 1994) . These alanine mutants and truncated receptors are not phosphorylated and signal more robustly than their wild type counterparts, a result that would be explained if phosphorylation were linked to receptor inactivation Shapiro et al., 1996) . Finally, GRK family members may not be the only kinases capable of phosphorylating PAR1. Ido et al. (2000) have recently identi®ed a 33 kDa kinase capable of phosphorylating the C-terminus of PAR1 fused to GST. As yet little is known about the role of this kinase in regulating PAR1 signaling in cells that normally express the receptor.
The carboxyl tail of PAR1 also participates in receptor shuto through its role in agonist-induced receptor internalization and tracking (Hein et al., 1994; Trejo and Coughlin, 1999; Trejo et al., 1998) (Figure 1) . For a number of other G protein coupled receptors, it has been shown that internalization can contribute to receptor resensitization, enabling the receptors to again be responsive to agonists when they recycle back to the cell surface. As already described, PAR family members represent an exception to this rule since once cleaved, they cannot be activated a second time by the same protease. Information about the internalization and tracking of PAR1 and, to a lesser extent, PAR2 has been obtained by several groups of investigators (BoÈ hm et al., 1996; Hoxie et al., 1993; Woolkalis et al., 1995b; Hein et al., 1994; DeÂ ry et al., 1999) . In most types of cells, PAR1 and PAR2 are rapidly internalized after agonist stimulation. In megakaryoblastic cell lines, *85% of PAR1 is sequestered into coated pits and then endosomes within 1 min of activation (Hoxie et al., 1993) . In endothelial cells, ®broblasts, and epithelial cells, the internalization of PARs is not as complete, with rapid internalization of at most *60% of cell surface receptors. Most of the internalized receptors are transferred to lysozomes, but the sorting is not completely ecient and in megakaryoblastic cell lines in particular as much as 40% of the cleaved receptors are recycled back to the cell surface (Hoxie et al., 1993) . The physiological relevance of this recycling is unknown. To our knowledge, it has been observed and reported only in the megakaryoblastic cell lines.
The relative contributions of receptor internalization and uncoupling to the termination of signaling through PAR1 is still under investigation, as is the necessity of receptor phosphorylation. Mutagenesis studies have been used to dissect the role of dierent domains in the receptor C-terminus to these events. found that a PAR1 variant in which all of the C-terminal serine and threonine residues were mutated to alanine is defective in both signal termination and receptor internalization. Phosphorylation was shown to occur at multiple sites in the receptor tail, and one region (residues 391 ± 406) was found to be critical for receptor uncoupling by GRK family members. However, when serine and threonine residues in this region were mutated to alanine there was little eect on receptor internalization, suggesting that other sites of phosphorylation are sucient to support internalization, and that dierent mechanisms may regulate internalization and uncoupling. Complete replacement of the C-terminus of PAR1 with the corresponding region from substance P receptors changes the tracking characteristics of PAR1 (internalization followed by targeting to lysozomes) to the tracking characteristic of native substance P receptors (internalization followed by recycling) (Trejo et al., 1998) .
What about PAR family members other than PAR1? The limited information that is available about PAR2 suggests that it is regulated in much the same manner as PAR1 (DeÂ ry et al., 1999) . PAR4, on the other hand, appears to not be phosphorylated and is internalized with slower kinetics than PAR1 .
Cell type specific variations
The fate of PAR1 and the mechanisms involved in signal termination and receptor replacement appear to vary somewhat among cell types. The high eciency of PAR1 internalization and the increased frequency of receptor recycling in megakaryoblastic HEL cells has already been described. Chen et al. (1996) expressed human PAR1 in Sf9 insect cells, and showed that both thrombin and SFLLRN induced an increase in intracellular Ca 2+ which lasted up to 12 min and was unaected by washout of agonist peptide or hirudin treatment. Signaling was unusually persistent unless the cells were treated with thermolysin, a protease that can remove the tethered ligand domain. This would suggest that in these cells the PAR1 tethered ligand is able to signal continuously, presumably due to the absence of appropriate signal termination systems. Examples of proteolytic termination of PAR signaling have not been demonstrated in mammalian cells, but a recent paper suggests that after a PAR is proteolytically activated, modi®cation or sequestration of the cleaved N-terminus may play a role in ending tethered ligandinduced signals . Human platelets, which would normally be called upon to respond to thrombin only once, internalize a comparatively low percentage of activated PAR1, leaving much of the cleaved PAR1 on their surface following exposure to thrombin (Molino et al., 1997a) . Some of it is shed into the microvesicles that form when platelets are activated by thrombin, particularly in the presence of collagen. Since platelets lack the ability to Figure 2 tracking and replacement of PAR1. Once activated by thrombin or an agonist peptide, PAR1 is desensitized and then usually cleared from the cell surface. Most of the internalized receptors are delivered to lysozomes, but in megakaryoblastic cell lines recycling can occur and in platelets some of the activated PAR1 is shed into microvesicles. In endothelial cells, most of the activated PAR1 is cleared and then replaced with intact receptors from an intracellular reservoir that does not exist in platelets synthesize large amounts of protein, cleaved PAR1 cannot be replaced. In contrast, endothelial cells and ®broblasts can be repeatedly exposed to thrombin and are capable of responding more than once. Their ability to do so is supported by the presence of an intracellular pool of intact receptors that does not exist in platelets (Hein et al., 1994; Woolkalis et al., 1995b; Molino et al., 1997a) . In the case of endothelial cells, this reservoir of intact receptors is capable of replenishing the cell surface with intact receptors in 1 ± 2 h, even in the presence of protein synthesis inhibitors. In endothelial cells, this pool is associated with an intracellular tubulovesicular network that has not been precisely de®ned (Horvat and Palade, 1995; Woolkalis et al., 1995b) . In ®broblasts Hein et al. (1994) localized this pool to a golgi-like domain. In these compartments, receptors are protected from extracellular proteases and can be rotated to the cell surface to replace cleaved receptors without the delay needed to synthesize new receptors. This greatly shortens the time needed for restoring protease responses. A similar mechanism is thought to apply to PAR2 (Molino et al., 1997c) .
Conclusion
In conclusion, 10 years after the original cloning and initial characterization of PAR1, much that was originally proposed about the receptor has held up well. A total of four family members have been described, at least three of which have now been knocked out in mice. The major contribution of PAR family members to thrombin responses in platelets and endothelial cells has been well-established. On the other hand, the role of PAR family members in vascular development, tissue invasion and tumor metastasis is just beginning to be understood, as is the potential for modulating these events with appropriate inhibitors. The development of antagonists for PAR1 activation has been partially successful, but the clinical utility of the antagonists still remains to be established, particularly in cases where more than one PAR family member contribute to the thrombin response. Finally, the basic mechanism for PAR1 activation remains generally applicable to other members of the family, but the ability of cleaved PAR1 to transactivate intact PAR2 and the ability of PAR3 to support activation of PAR4 shows that these unusual members of the G protein coupled receptor family still retain a few surprises.
What are the outstanding questions remaining in PAR biology? Some are obvious and relate directly to the cellular eects of thrombin. Will the PAR4 knockout mouse yield an animal whose platelets are entirely unresponsive to thrombin and, if so, what will the hemostatic consequences of loss of thrombin signaling in platelets be? What is the role of thrombin signaling in mammalian development? Since the description of embryonic lethality in the PAR1 knockout mouse there has been little progress in answering this question. What are the roles of PAR2 and human PAR3 in vivo? Knockout mice de®cient in these receptors have either not provided an obvious answer to this question (in the case of PAR2) or have demonstrated critical species dierences in expression (in the case of PAR3) that prevent interpretation for human biology. PAR2 function will likely be elucidated by experiments addressing more speci®c hypotheses. PAR3 and non-platelet PAR4 functions in human tissues will be a dicult challenge without the bene®t of an appropriate genetic model. Finally, given the large number of serine proteases why is it that such a limited repertoire of PARs has evolved? The straightforward genomic structure and overall homology of these receptors suggests that availability of the human genome sequence will allow fairly quick identi®cation of novel PARs, but analysis of the data available supports the fact that this is a fairly small family of receptors. Are there more distantly related receptors yet to be discovered? Clearly signi®cant work remains to determine the roles of the known PARs and the extent of the PAR family.
